Ocular Therapeutix Inc
Change company Symbol lookup
Select an option...
OCUL Ocular Therapeutix Inc
GOOG Alphabet Inc
BAC Bank of America Corp
ED Consolidated Edison Inc
FRAN Francesca's Holdings Corp
CWBHF Charlotte's Web Holdings Inc
SALM Salem Media Group Inc
FUN Cedar Fair LP
NWFFX American Funds New World Fund® Class F-1

Health Care : Pharmaceuticals | Small Cap Blend
Company profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Closing Price
Day's Change
0.39 (4.41%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Surgical Sealants And Adhesives Global Market Report 2020-30: Covid 19 Growth and Change

8:19 am ET July 16, 2020 (Globe Newswire) Print

Reportlinker.com announces the release of the report "Surgical Sealants And Adhesives Global Market Report 2020-30: Covid 19 Growth and Change" - https://www.reportlinker.com/p05932649/?utm_source=GNW

), Sanofi, Ocular Therapeutix Inc., and Sealantis Ltd.

The global surgical sealants and adhesives market is expected to decline from $2.21 billion in 2019 to $1.33 billion in 2020 at a compound annual growth rate (CAGR) of -39.8%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing. The treatment for patients suffering from COVID-19 has taken precedence as a result of which numerous non-essential surgeries have been cancelled or postponed, decreasing the demand for surgical sealants and adhesives. The market is then expected to recover and reach $2.81 billion in 2023 at a CAGR of 28.3%.

The surgical sealants and adhesives market consists of revenue generated from the sales of surgical sealants and adhesives. Surgical sealants and adhesives are materials used to repair injured tissues and prevent air & fluid leakages during or after the surgeries. These are used for minimizing blood losses, replacing staples and sutures for better closure, and strengthening wound area without limiting the tissue movement.

North America was the largest region in the surgical sealants and adhesives market in 2019. Asia Pacific is expected to be the fastest-growing region in the surgical sealants and adhesives market in the forecast period.

In January 2018, Baxter International Inc., a global medical products company committed to advanced surgical innovations, announced the acquisition of two hemostat and sealant products: Recothrom and Preveleak surgical sealant, from Mallinckrodt plc for an amount of $ 153 million. This acquisition is aimed at broadening the surgical product portfolio of Baxter International Inc. With Recothrom, Baxter International Inc is providing additional options for innovative hemostatic products to surgeons to handle different severities of bleeding, whereas Preveleak is an addition to the company's advanced surgical sealants portfolio. Mallinckrodt Pharmaceuticals is a UK-based manufacturer of specialty pharmaceuticals, imagining agents and generic drugs.

The surgical sealants and adhesives market covered in this report is segmented by product into biological sealants; synthetic sealants; semi-synthetic sealants. It is also segmented by indication into tissue sealing; tissue engineering; hemostasis and by end-use into hospitals; clinics; others.

The advances in surgical procedures are anticipated to hinder the growth of surgical sealants and adhesives market. Minimal invasive surgeries are replacing conventional surgical procedures, eliminating the complications including bleeding and air leakage and therefore, limiting the use of any surgical sealants and adhesives. According to the American Society of Plastic Surgeons (ASPS), in 2018, approximately 18 million people underwent surgical and minimally invasive cosmetic procedures in the USA. Hence, the growing number of minimally invasive surgeries and other substitutes for the conventional surgical processes is predicted to impact the growth of the market over the forthcoming years.

Several companies operating in the market are focusing on product portfolio expansion into untapped geographies. For instance, in January 2020, Terumo Corporation announced the launch of AQUABRID, new surgical sealants in the EMEA market. AQUABRID is specially developed for aortic procedures to stop bleeding during and post surgeries. The company earlier introduced this product in Japan in 2014 under the brand name Hydrofit and is under the process of registration in Eastern Europe, the Middle East and Africa.

The rising number of surgical procedures is predicted to contribute to the growth of surgical sealants and adhesives market. In recent years, the continuous surge in surgical procedures is registered attributing to the growing prevalence of obesity and other lifestyle diseases, increasing incidence of spinal and sports-related injuries, and rising geriatric population. The old-age population is more prone to chronic, heart, and other diseases, thereby undergoing surgical procedures. According to the United Nations Department of Economic and Social Affairs, the number of people over the age of 65 is projected to increase from 703 million in 2019 to 1.5 billion by 2050, globally.

Read the full report: https://www.reportlinker.com/p05932649/?utm_source=GNW

About Reportlinker

ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.